B+
Bull case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
XBIO
Xenetic BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Completion of the Santersus transaction on favorable terms could give the combined company a more valuable development portfolio, while DNase translational progress and recurring PolyXen royalties provide additional optionality. Q2 royalty revenue increased about 12% year over year, and the approved exploratory lymphoma study offers a path toward human evidence.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Cash declined to approximately $6.5 million at June 30, 2026, while the company remained loss-making and strategic-review legal expenses increased, raising future financing and execution risk. [#SEC-8K-2026-08-07]
Momentum
63
Value
57
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.75 · Bull $4.00 · Bear $0.65Analysis 2026-09-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-29 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-29
Investment thesis
As of 2026-10-29
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-29. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum63 · Δ7d -
Value57 · Δ7d +0.2
Sentiment52 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.2.
Contradictions & invalidation
- • Cash declined to approximately $6.5 million at June 30, 2026, while the company remained loss-making and strategic-review legal expenses increased, raising future financing and execution risk. [#SEC-8K-2026-08-07]
- • DNase programs remain dependent on successful translation from preclinical findings and an exploratory investigator-initiated study into reproducible clinical benefit. [#SEC-8K-2026-08-07]
- • The proposed transaction is effectively transformative: expected 85% ownership for Santersus holders implies substantial dilution and leaves legacy holders exposed to closing, valuation and integration uncertainty.
Catalyst clock
2026-11-15
Cash, royalty and transaction-cost update
Lead driver: Value · See fundamentals
Momentum
63
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.2
Sentiment
52
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 62.9 / Value 57.3 / Sentiment 51.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-17. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$1.75
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$4.97M
Beta
2.30
Shares Out
2.34M
P/E (TTM) · Derived
-1.3
P/S (TTM)
1.76
P/FCF (TTM) · Derived
-1.85
Rev YoY
+12.0%
EPS YoY
-9.3%
Gross Margin
+94.4%
Op Margin
-81.0%
Net Debt
-$7.88M
Current Ratio
7.43
As of 2026-10-29 • Updated nightlySource: Internal modelMethods & Data